Grail Shares Plunge 45.6% Following Disappointing Galleri Test Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy GRAL?
Source: Fool
- Disappointing Test Results: Grail's Galleri multi-cancer screening test failed to achieve statistical significance in a three-year trial involving 142,000 participants, resulting in a 45.6% stock price drop in February, which directly impacted investor confidence and market expectations.
- Insurance Payment Risks: Although the Galleri test showed a substantial increase in early-stage cancer detections, the failure to reduce late-stage diagnoses raised concerns among insurers about covering the test, exacerbating the stock's decline.
- Trial Design Reflection: CEO Bob Ragusa noted that the trial was designed with limited information six years ago, and the company plans to extend the follow-up period by six months to a year, potentially leading to improved Stage IV detection outcomes in the future.
- High-Risk Investment: Despite the current stock slump, some investors remain optimistic about Grail, believing that future follow-up data may alter market perceptions of the Galleri test; however, investing in Grail shares remains a high-risk, high-reward proposition.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRAL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRAL
Wall Street analysts forecast GRAL stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 49.820
Low
38.00
Averages
60.86
High
83.71
Current: 49.820
Low
38.00
Averages
60.86
High
83.71
About GRAL
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Grail Shares Plunge 45.6% Following Disappointing Galleri Test Results
- Disappointing Test Results: Grail's Galleri multi-cancer screening test failed to achieve statistical significance in a three-year trial involving 142,000 participants, resulting in a 45.6% stock price drop in February, which directly impacted investor confidence and market expectations.
- Insurance Payment Risks: Although the Galleri test showed a substantial increase in early-stage cancer detections, the failure to reduce late-stage diagnoses raised concerns among insurers about covering the test, exacerbating the stock's decline.
- Trial Design Reflection: CEO Bob Ragusa noted that the trial was designed with limited information six years ago, and the company plans to extend the follow-up period by six months to a year, potentially leading to improved Stage IV detection outcomes in the future.
- High-Risk Investment: Despite the current stock slump, some investors remain optimistic about Grail, believing that future follow-up data may alter market perceptions of the Galleri test; however, investing in Grail shares remains a high-risk, high-reward proposition.
See More
Grail Lowers Cash Burn Guidance to $290 Million Amid Trial Setback
- Cash Burn Guidance: Grail's CFO announced during the Q3 2025 earnings call that the company expects its cash burn for the year to be no more than $290 million, reflecting a strategic financial adjustment following the clinical trial failure.
- Stock Price Plunge: The stock price of Grail plummeted approximately 50% after the NHS Galleri trial missed its primary endpoint, resulting in investors losing nearly half of their holdings, indicating a pessimistic market sentiment regarding the company's future prospects.
- Cash Runway Assurance: Despite the setbacks, the CEO stated that the company's cash runway is projected to extend into 2030, providing sufficient funding to achieve major milestones such as FDA PMA submission and full clinical utility results from the NHS Galleri study, demonstrating confidence in future objectives.
- Shareholder Rights Protection: The company encourages shareholders who suffered losses to submit their information to discuss legal rights, indicating that Grail is actively working to protect investor interests amid significant financial challenges.
See More
Following Grail's Study Setback, What Remains for Cancer Blood Screening?
- Stock Performance: Grail's stock experienced a significant decline, losing half of its value last Friday.
- Market Reaction: The drastic drop in stock price indicates a negative market reaction, potentially affecting investor confidence.
See More
Grail Stock Surges Over 16% Amid Optimism for Future Developments
- Stock Rebound: Grail's stock surged over 16% by midday, following several days of sharp declines, indicating market optimism for future developments despite the Galleri multi-cancer early detection test missing its primary endpoint.
- Clinical Trial Results: The trial, involving 142,000 participants, failed to show a statistically significant reduction in Stage III and IV cancers across 12 deadly indications, although CEO Bob Ragusa stated this would not impact FDA approval likelihood.
- Insurance Payment Risks: The failure to meet the primary endpoint raises concerns that insurers may be reluctant to cover the test, potentially affecting market acceptance and future revenue streams.
- Follow-Up Data Anticipation: Analysts noted that Grail is extending the trial to gather 6 to 12 months of follow-up data, hoping this data will validate the study's effectiveness, although Ragusa acknowledged a longer follow-up period should have been allowed.
See More
Grail Shares Plunge 50% Amid Clinical Trial Setback
- Stock Price Volatility: Grail's shares plummeted by 50% last Friday, dropping from approximately $102 to $49, reflecting investor concerns about the company's outlook after a remarkable rise from $19 to $110 in 2025.
- Clinical Trial Setback: The company announced that its large clinical trial in England failed to meet the primary endpoint of reducing Stage III-IV cancer diagnoses, raising doubts about the effectiveness of the Galleri test and impacting market confidence.
- Market Reaction: Following the trial results, Grail's stock fell by 14.3% in a single day, reducing its market capitalization to $2 billion, indicating significant investor anxiety regarding its future profitability.
- Uncertain Medicare Coverage: Grail has been striving to secure Medicare coverage for the Galleri test, but the disappointing trial results cast doubt on this goal, potentially affecting the company's long-term strategic direction.
See More
Grail Stock Plummets 16% Amid Trial Failure
- Trial Results Disappoint: Grail's Galleri multi-cancer early detection trial failed to meet its primary endpoint, showing no statistically significant reduction in Stage III-IV cancer detection rates, leading to a stock price drop of over 16%, posing a significant challenge to the company's future market acceptance.
- Market Reaction Intense: As of 12:40, Grail's stock price fell by 15.16%, currently priced at $42.60 with a market cap of $2 billion and a trading volume of 4.6 million shares, indicating strong investor reaction and concerns about the company's outlook following the trial results.
- Insurance Payment Barriers: The trial's inability to demonstrate that the Galleri test effectively reduces late-stage cancer incidence may lead healthcare insurers to hesitate in covering the test, impacting Grail's revenue and market penetration capabilities.
- Uncertain Future Outlook: Although management noted plans to extend the trial's follow-up period and suggested that diagnostic resolution times may improve with physician experience, the current results cast a pessimistic shadow over the test's future market potential.
See More
Grail Shares Plunge 45.6% Following Disappointing Galleri Test Results
- Disappointing Test Results: Grail's Galleri multi-cancer screening test failed to achieve statistical significance in a three-year trial involving 142,000 participants, resulting in a 45.6% stock price drop in February, which directly impacted investor confidence and market expectations.
- Insurance Payment Risks: Although the Galleri test showed a substantial increase in early-stage cancer detections, the failure to reduce late-stage diagnoses raised concerns among insurers about covering the test, exacerbating the stock's decline.
- Trial Design Reflection: CEO Bob Ragusa noted that the trial was designed with limited information six years ago, and the company plans to extend the follow-up period by six months to a year, potentially leading to improved Stage IV detection outcomes in the future.
- High-Risk Investment: Despite the current stock slump, some investors remain optimistic about Grail, believing that future follow-up data may alter market perceptions of the Galleri test; however, investing in Grail shares remains a high-risk, high-reward proposition.
See More
Grail Lowers Cash Burn Guidance to $290 Million Amid Trial Setback
- Cash Burn Guidance: Grail's CFO announced during the Q3 2025 earnings call that the company expects its cash burn for the year to be no more than $290 million, reflecting a strategic financial adjustment following the clinical trial failure.
- Stock Price Plunge: The stock price of Grail plummeted approximately 50% after the NHS Galleri trial missed its primary endpoint, resulting in investors losing nearly half of their holdings, indicating a pessimistic market sentiment regarding the company's future prospects.
- Cash Runway Assurance: Despite the setbacks, the CEO stated that the company's cash runway is projected to extend into 2030, providing sufficient funding to achieve major milestones such as FDA PMA submission and full clinical utility results from the NHS Galleri study, demonstrating confidence in future objectives.
- Shareholder Rights Protection: The company encourages shareholders who suffered losses to submit their information to discuss legal rights, indicating that Grail is actively working to protect investor interests amid significant financial challenges.
See More
Following Grail's Study Setback, What Remains for Cancer Blood Screening?
- Stock Performance: Grail's stock experienced a significant decline, losing half of its value last Friday.
- Market Reaction: The drastic drop in stock price indicates a negative market reaction, potentially affecting investor confidence.
See More
Grail Stock Surges Over 16% Amid Optimism for Future Developments
- Stock Rebound: Grail's stock surged over 16% by midday, following several days of sharp declines, indicating market optimism for future developments despite the Galleri multi-cancer early detection test missing its primary endpoint.
- Clinical Trial Results: The trial, involving 142,000 participants, failed to show a statistically significant reduction in Stage III and IV cancers across 12 deadly indications, although CEO Bob Ragusa stated this would not impact FDA approval likelihood.
- Insurance Payment Risks: The failure to meet the primary endpoint raises concerns that insurers may be reluctant to cover the test, potentially affecting market acceptance and future revenue streams.
- Follow-Up Data Anticipation: Analysts noted that Grail is extending the trial to gather 6 to 12 months of follow-up data, hoping this data will validate the study's effectiveness, although Ragusa acknowledged a longer follow-up period should have been allowed.
See More
Grail Shares Plunge 50% Amid Clinical Trial Setback
- Stock Price Volatility: Grail's shares plummeted by 50% last Friday, dropping from approximately $102 to $49, reflecting investor concerns about the company's outlook after a remarkable rise from $19 to $110 in 2025.
- Clinical Trial Setback: The company announced that its large clinical trial in England failed to meet the primary endpoint of reducing Stage III-IV cancer diagnoses, raising doubts about the effectiveness of the Galleri test and impacting market confidence.
- Market Reaction: Following the trial results, Grail's stock fell by 14.3% in a single day, reducing its market capitalization to $2 billion, indicating significant investor anxiety regarding its future profitability.
- Uncertain Medicare Coverage: Grail has been striving to secure Medicare coverage for the Galleri test, but the disappointing trial results cast doubt on this goal, potentially affecting the company's long-term strategic direction.
See More
Grail Stock Plummets 16% Amid Trial Failure
- Trial Results Disappoint: Grail's Galleri multi-cancer early detection trial failed to meet its primary endpoint, showing no statistically significant reduction in Stage III-IV cancer detection rates, leading to a stock price drop of over 16%, posing a significant challenge to the company's future market acceptance.
- Market Reaction Intense: As of 12:40, Grail's stock price fell by 15.16%, currently priced at $42.60 with a market cap of $2 billion and a trading volume of 4.6 million shares, indicating strong investor reaction and concerns about the company's outlook following the trial results.
- Insurance Payment Barriers: The trial's inability to demonstrate that the Galleri test effectively reduces late-stage cancer incidence may lead healthcare insurers to hesitate in covering the test, impacting Grail's revenue and market penetration capabilities.
- Uncertain Future Outlook: Although management noted plans to extend the trial's follow-up period and suggested that diagnostic resolution times may improve with physician experience, the current results cast a pessimistic shadow over the test's future market potential.
See More
